Intellia Therapeutics
40 Erie Street
Cambridge
Massachusetts
02139
United States
Tel: (857) 285-6200
Website: http://intelliatx.com/
About Intellia Therapeutics
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.
Change life stories with genome editing therapies!
Stock Symbol: NTLA
Check out our Intellia office space!
172 articles with Intellia Therapeutics
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
2/24/2022
Intellia Therapeutics, Inc., a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, reported operational highlights and financial results for the fourth quarter and year ended December 31, 2021.
-
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
2/23/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies.
-
Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.
-
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
2/17/2022
Intellia Therapeutics, Inc. today announced that it will be hosting two virtual investor events in February.
-
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
2/15/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd., an innovative company dedicated to developing optimally engineered natural killer (NK) cell therapies to cure patients with cancer, today announced a licensing and collaboration agreement.
-
Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.
-
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
2/3/2022
Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategies.
-
On Thursday, Intellia announced it had paid Rewrite shareholders $45 million upfront. Additionally, the transaction involved a transfer of $155 million in the form of Intellia common stock and cash.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
-
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
1/6/2022
Intellia Therapeutics, Inc. today outlined its expected milestones and the following strategic priorities for 2022.
-
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
1/5/2022
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.
-
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
1/5/2022
Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases.
-
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
-
BioSpace Movers & Shakers, Dec. 24
12/24/2021
With all eyes on a new year, life sciences companies and organizations are making last-minute appointments to strengthen their leadership teams and board with these Movers & Shakers. -
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
12/20/2021
Intellia Therapeutics, Inc. today announced the appointment of Derek Hicks to a newly created position as Executive Vice President, Chief Business Officer.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
12/13/2021
Intellia Therapeutics, Inc. today announced that the first patient has been dosed with NTLA-2002, the company’s in vivo CRISPR/Cas9 genome editing candidate being developed as a single-dose therapy to prevent attacks in people living with hereditary angioedema (HAE).
-
Clinical Catch-Up: November 22-26
11/29/2021
Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look. -
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!